Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Completed · Phase 2 · Has a placebo group

Conditions studied: Motion Sickness

In brief

Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.

Key facts

Study ID

NCT03772340

Run by

Vanda Pharmaceuticals

People needed

126

Starts

2018-12-20

Expected to finish

2019-06-27

Last updated by the study team

2025-05-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive);
• Body Mass Index (BMI) of ≥18 and <40 kg/m2;
• History or symptoms consistent with motion sickness

You may not qualify if…

• Chronic nausea due to condition other than motion sickness;
• A positive test for drugs of abuse at the screening or evaluation visits;
• Clinically significant deviation from normal clinical laboratory results

Where it is running

• Vanda Investigational Site — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.